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months prior to duloxetine initiation (defined as no duloxetine pill coverage in the
previous 90 days) were identified via administrative claims. The use of pain related
medications was assessed during the 6 and 12 months prior to duloxetine
initiation.RESULTS:The study identified 1682, 308, 1044, 1363, 4255, and 5189 in the
MDD, GAD, DPNP, FM, OA, and low back pain (LBP) cohorts in 2009-2010. Antide-
pressant use during the 12 months prior to initiation was common, and was high-
est among MDD (87.2%) and GAD patients (83.4%). The use of anticonvulsants was
comparable between cohorts, but highest among patients with DPNP (60.0%) and
FM (54.7%), and between 47.0-52.4% among other cohorts. There was varied use of
opioids across cohorts, ranging from 63.3% (GAD) to 84.7% (LBP). Non-steroidal
anti-inflammatory drugs utilization varied with the lowest use among GAD pa-
tients (30.2%) and the highest among OA patients (45.8%). Utilization of muscle
relaxants widely ranged from 22.0% (DPNP) to 40.4% (FM). Use of pain medication
during the 6 months prior was similar, but was generally 10-15% lower. Use pat-
terns in 2007 and 2008 were similar.CONCLUSIONS:Across disease states, patients
used a variety of medications prior to the initiation of duloxetine. Patterns of use
have largely stayed the same from 2007 through 2010.
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OBJECTIVES: For distribution biologic agents in patients with JIA in Russia, data
about epidemiology, used drugs and their impact on functional status are
necessary. METHODS: Records were examined for 6 months retrospectively. Data
were collected via medical chart review by rheumatologists from 11 regions of
Russia. Functional status was assessed with CHAQ questionnaire. Inclusion crite-
ria: age (younger than 18 years), minimum 6 months since diagnosis of JIA and
availability of 6 months retrospective data. Recruitment: no more than 30% pa-
tients received biologic therapy. Disease-specific criteria: about 50% had oligoar-
thritis, 30-40% - polyarthritis and 10-20% - systemic form. Analysis was performed
with methods of descriptive statistic, parametric and non-parametric criteria.
RESULTS: Data on 405 patients were obtained. Ratio (male:female) was 1:1.6. Av-
erage duration of disease was 5 years. 72% had a disability status caused by JIA. 43%
had mild functional disorders; 32% - moderate; 23% - severe disorders, and only 2%
had no functional disorders. Seventy-two percent patients in subgroup without
functional disorders got biologic therapy, 30% and 28% got biologic agents in sub-
groups with mild and moderate disorders respectively. In subgroup with severe
disorders 41% received biologic therapy; 18% patients with oligoarthritis got bio-
logical agents; 40% - with polyartritis, 54% - with systemic form. CONCLUSIONS:
Prescription of biologic therapy increases in case of more severe form of JIA. Direct
relationship between biologic therapy prescription and functional status was not
revealed.
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OBJECTIVES: Disease-modifying anti-rheumatic drugs (DMARDs) are the corner-
stone of rheumatoid arthritis (RA) pharmacotherapy and should be initiated
promptly after RA diagnosis. We examined trends in DMARD use among RA pa-
tients in Quebec, and factors correlated with DMARD initiation in newly diagnosed
RA. METHODS: Quebec administrative health databases were used to identify RA
subjects and their claims for medical and pharmaceutical services between Janu-
ary 1, 2002 and December 31, 2008. To describe DMARD use, cross-sectional anal-
yses were performed on November 1 of each year. For subjects newly diagnosed
with RA, multivariable logistic regressions were used to identify possible predictors
of DMARD initiation at 12 months and Kaplan-Meier curves to define the probabil-
ity of initiating a DMARD over time. RESULTS: A total of 32,533 subjects were
included (mean age: 67.5 years; 70.4% female). Over the study period, the percent-
age of subjects on a DMARD increased from 42.0% (November 2002) to 43.2% (No-
vember 2008). Being followed by a rheumatologist (vs. GP) was the strongest pre-
dictor of DMARD initiation (OR4.39; 95%CI: 3.80-5.08). The use of NSAIDs,
corticosteroids, and opioids in the year prior to cohort entry and the calendar year
of cohort entry had a positive effect on DMARD initiation, whereas age, comorbidity
score, and the use of acetaminophen had a negative effect. For biologics, calendar
year was the strongest predictor (OR 2007 vs. 200210.78; 95%CI: 2.45-47.37). Of
subjects newly diagnosed in 2002, 0.1% had a biologic initiated within one year,
while for those newly diagnosed in 2007 the percentage was 1.3%. In any newly
diagnosed subjects, averaged over 2002-2007, the probability of having initiated
any DMARDs at 12 months was 38.5% (47.8% for those followed by a
rheumatologist). CONCLUSIONS: Despite encouraging signs for earlier aggressive
RA management, DMARD use appears to be sub-optimal in Quebec. Use of DMARDs
was much higher among subjects followed by a rheumatologist.
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OBJECTIVES: In the last decade, several biological agents (biologics), including anti-
TNFs, have been approved for use in Rheumatoid Arthritis (RA), thus revolutioniz-
ing treatment. Despite the widespread availability of these drugs through Europe,
patient access differs significantly among countries. We aimed to compare the
share of RA patients being treated with biologics in each country and study the
factors that influence the different shares, with focus on the market potential for
Portugal. METHODS: A multivariable linear regression model using SPSS 10.0 was
built to identify which factors best explain a country’s share of prevalent RA pa-
tients treated with biologics. This share was calculated based on IMS Health re-
ported unit sales converted into annualized treatments by applying defined daily
doses by WHO. RESULTS: A total of 21 independent variables were collected for
each of the 15 European countries, including demographic, economic, funding-
related, disease-related and biologics-related data. Model results (Adjusted R2
0,953; SE0,0456) indicated that a country’s share of prevalent RA patients treated
with biologics is mostly explained by its GDP per capita (0.006; p0.0001), the
share of biologics treatments per dispensing channel - hospital vs. Retail
(0.046; p0.149) and the usage of methotrexate (0.26; p0.05). Based on
these variables and their expected evolution we estimated the overall market po-
tential for the Portuguese market, define 4 country clusters and understand Portu-
gal’s relative position among the 15 countries. Share of RA prevalent patients
treated with methotrexate in Portugal may be standing 5 years behind comparable
countries such as UK, France, Germany or Spain, thus impacting the share of pa-
tients treated with biologics. CONCLUSIONS: Portugal presents the lowest share of
RA prevalent patients treated with biologics of all selected countries. Lower GDP
per capita, biologics exclusively dispensed in hospital settings and a low consump-
tion of methotrexate are the best explanatory factors for this reality.
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OBJECTIVES: To assess treatment patterns among patients with shoulder osteoar-
thritis (OA).METHODS:Data from Thomson MarketScan, a large national managed
care population, was used to identify patients with a shoulder OA diagnosis in the
first 6 months of 2005 (i.e., the index date). The 360 days post index (identification
period) was used to establish baseline treatments (i.e., conservative management
(pharmaceutical and physical therapy), steroid injections and shoulder surgery).
Patients were required to be continuously eligible for 54 months post-index and
were excluded if they had a shoulder surgery claim in the identification period.
Four cohorts were followed based on the baseline treatments: C1- conservative
treatment; C2- conservative treatment and at least one steroid injection; C3- at
least one steroid injection; C4- no treatment claims. Progression to additional treat-
ments was evaluated descriptively from day 361 to 1260 in 180 increments. Logistic
regression was used to model the odds or having a claim for a treatment. RESULTS:
A total of 3646 patients met the analysis criteria (C1, n2,815(77.2%); C2,
n171(4.7%); C3, n27(0.7%); C4, n633(17.4%)). The distribution was split evenly
between males (50.2%) and females (49.8%). Patients who received steroid injec-
tions in the identification period had the greatest likelihood of having a steroid
injection in the observation period (C1-19.2%;C2-43.9%;C3-44.4%;C4-14.1%). The
percentage with shoulder surgery was 6.4%, 15.2%, 11.1% and 6.5% for C1 to C4,
respectively. Patients with steroids in the observation period (C2 and C3) were more
likely to have surgery in the first year of observation. Logistic regression showed
that females who had steroid injections (C2 and C3 combined) had odds of surgery
that were 2.9 times greater than females with no treatments (C1). CONCLUSIONS:
The most significant predictor of surgery was presence of steroid injections. Rates
of steroid injections and surgery differed based on presence of pre-existing treat-
ments.
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OBJECTIVES: To evaluate the effect of a quality improvement intervention that
provided financial incentives to physicians to encourage adoption of best practices,
coupled with organizational support to improve care management. The interven-
tion, implemented at two pilot sites in Washington State, was aimed at reducing
work disability for patients with occupational injuries or illnesses treated within
the workers’ compensation system. METHODS: At each pilot site, a Center for
Occupational Health and Education (COHE) was established to recruit physicians
for the pilot and to implement the intervention. We conducted a prospective non-
randomized intervention study, with a non-equivalent comparison group, using
difference-in-difference models. The intervention group included patients (31,520)
treated from July 2004 through June 2007 by COHE physicians (n  300). The com-
parison group included patients (40,176) treated by non-COHE physicians practic-
ing in the pilot target areas. The baseline (pre-intervention) period was specified as
July 2001 to June 2003 and included 33,910 patients treated by COHE and non-COHE
physicians. We used logistic regression and generalized linear models to analyze
four outcomes at one year following injury: off work and on disability, disability
days, and disability costs and medical costs per claim. RESULTS: COHE patients
were less likely to be off work and on disability at one year post injury (OR  .79,
P  0.003). The COHE was associated with a statistically significant (p  .01)
reduction in disability days (16.5%) and disability costs (23.7%), and with a non-
signific0ant (p  0.13) reduction of 6.7% in medical costs. Patients treated by
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COHE physicians who more often adopted occupational health best practices
had 57% fewer disability days (p  0.001) compared with patients treated by
COHE physicians who less frequently adopted best practices. CONCLUSIONS:
Physician financial incentives, coupled with care management support, can im-
prove outcomes and reduce costs for patients receiving occupational health care.
Muscular-Skeletal Disorders – Research on Methods
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OBJECTIVES: Kyphosis due at least one vertebral compression fracture (VCF) is
prevalent among osteoporotic patients, resulting in well documented symptoms
and impact on functioning and well-being. Assessing health outcomes of interven-
tions concentrates on consequences of back pain, omitting relevant aspects of
increased morbidity. A three-part study led to development of a conceptual mea-
surement framework for comprehensive assessment of symptoms, impact and
treatment benefits in kyphosis. METHODS: We developed a literature-based
(PubMed, Medline) Disease Model (DM) for kyphosis for selecting and developing
outcome measures, as recommended by regulatory agencies. In-depth interviews
were conducted among patients (n10) and physicians (n10) to test the DM.
Physician respondents were PCPs or specialists currently treating patients with
osteoporotic kyphosis. Patient respondents were 50 years old with an osteopo-
rotic VCF 90 days prior. Relevant Patient-Reported Outcome instruments (PROs)
were evaluated for appropriateness in this population. RESULTS: The DM included
signs, symptoms, causes/triggers, exacerbations, and functional/well-being im-
pact of kyphosis. The DM content was largely confirmed by all respondents, how-
ever patients offered new concepts of emotional and functional impact and clini-
cians discounted psychosocial concepts (well-being and sleep impairment) and
added clinical evaluations of the spinal deformity. Related to these findings, PRO
instruments lacked adequate content validity or measurement properties for eval-
uating kyphosis outcomes. Close matches were the IOF Quality of Life question-
naire (Qualeffo-41) and the Osteoporosis Assessment Questionnaire (OPAQ),
though neither includes gastrointestinal or respiratory symptoms. CONCLUSIONS:
This study confirms the need for more comprehensive assessment of health out-
comes in kyphosis, because current approaches omit key concepts (gastrointesti-
nal and respiratory symptoms) and functional impact being a major cost-driver. A
comprehensive evaluation of the severity and impact of kyphosis requires clinician
evaluation of spinal deformity and patient-report of symptoms (spinal, respiratory,
GI) and functional impact and a more complete understanding of the unique infor-
mation provided by different measurements.
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OBJECTIVES: To compare the clinical effectiveness of abatacept and other biologic
Disease Modifying Anti-Rheumatic Drugs (DMARDs), as measured by Health As-
sessment Questionnaire (HAQ) score, in patients with rheumatoid arthritis (RA)
who have responded inadequately to methotrexate (MTX-IR) in the UK
environment.METHODS:A systematic literature review (conducted in line with UK
reimbursement environment) identified controlled trials investigating the efficacy
of abatacept (3 studies), adalimumab (2), certolizumab pegol (2), etanercept (2),
golimumab(1) and infliximab(2) in MTX-IR patients. The identified trials were com-
parable in design, included patients, and concomitant treatment (MTX). Mixed
treatment comparison analyses were performed on HAQ change from baseline
(CFB) at 24 and 52 weeks. Results were expressed as difference in HAQ CFB score
between treatments and expected HAQ CFB and the 95% Credible Interval (CrI) per
treatment at 24 and 52 weeks. RESULTS: The analysis of HAQ CFB at 24 weeks
showed that abatacept/MTX is more efficacious than MTX monotherapy (0.30,
95%CrI:0.42,,0.16) and shows small numeric differences versus other biologics/
MTX (range:0.11 to 0.9). The expected mean HAQ CFB at 24 weeks for abatacept
(0.57) was superior to placebo (0.27) and comparable to all the alternative treat-
ments (adjusted mean between 0.46 and 0.65). The findings at 52 weeks are in
line with those at 24-weeks, although no data was available for golimumab. Sce-
nario analyses confirmed the robustness of the findings. CONCLUSIONS: Abata-
cept in combination with MTX is expected to result in a comparable improvement
in functional status as measured in HAQ score and ACR responses as other biologic
agents in MTX-IR RA patients.
Neurological Disorders – Clinical Outcomes Studies
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OBJECTIVES: Both intramuscular interferon (IM IFN) -1a and fingolimod slow re-
duce progression and relapses among patients with multiple sclerosis (MS). In a
head-to-head trial, fingolimod demonstrated greater reductions in relapses, but no
difference in progression, compared to IM IFN--1a; fingolimod-treated patients
were at increased risk of some unintended treatment effects, however. Whether
the difference in efficacy between fingolimod and IM IFN--1a is offset by the
increased risk of unintended effects is unknown. The objective was to estimate the
net health benefit (NHB) of IM IFN--1a versus fingolimod. METHODS: A probabi-
listic Markov risk-benefit model was developed with three-month cycles and a
five-year time horizon (ten years in sensitivity analysis). Model inputs were ab-
stracted from the head-to-head trial, and incorporated intended (preventing pro-
gression and relapse) and serious unintended (cardiovascular events, serious in-
fections, and neoplasms) effects of treatment. Utilities for these were discounted at
5% annually, and combined using a minimum model. NHB was expressed in qual-
ity-adjusted life years (QALYs) per patient, with 95% credible intervals.RESULTS: In
a cohort of 1000 patients (mean age, 36 years), the NHB of treatment was 3.76
(3.30-4.08) QALYs with fingolimod and 3.73 (3.24-4.07) QALYs with IM IFN--1a over
five years. Fingolimod-treated patients accrued slightly more QALYs from intended
effects (3.88, vs. 3.82 QALYs for IM IFN--1a), but had higher QALY decrements from
unintended effects (-0.12, vs. -0.09 QALYs for IM IFN--1a). Findings were consis-
tent over a ten-year horizon. CONCLUSIONS: Even with greater relapse reduction
with fingolimod, both treatments have similar positive NHBs. This was driven by
similar disease progression rates between the treatments, and additional risks of
unintended effects with fingolimod. This model can assist clinicians and decision
makers in quantifying the trade-offs between intended and unintended treatment
effects, by jointly incorporating the benefits of slowing progression and reducing
relapses, with the risks of adverse events.
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OBJECTIVES: In the ALLEGRO Phase III clinical trial, 0.6 mg once daily laquinimod,
an oral treatment under development for the treatment of relapsing-remitting
multiple sclerosis (RRMS), showed a statistically significant 36% reduction in the
risk of confirmed disability progression according to the Expanded Disability Status
Scale (EDSS) versus placebo, in addition to a significant 23% reduction in the relapse
rate. The purpose of this analysis was to investigate health economic implications
of these efficacy results. METHODS: A computer model was developed to estimate
costs and health effects in the treatment of RRMS with laquinimod, allowing for
comparison against different treatment alternatives. The model used a 40-year
time horizon to capture long-term consequences, assuming that the treatment
duration would be 5 years in concordance with many other models in the field.
Efficacy data from the ALLEGRO trial and published cost and quality of life data for
Sweden were used to populate the model. As there is not yet an established market
price for laquinimod, the analysis focused on cost savings and gains in quality of
life. Costs and health effects were discounted at an interest rate of 3%. RESULTS:
Therapy with laquinimod during 5 years resulted in a gain of 0.29 quality adjusted
life years and societal cost offsets of EUR 58,000 over the modeled time period (0.11
Euro/Swedish Krona). On average, 0.5 relapses were also estimated to be avoided
during the treatment period. Over 40 years, patients spent 1.2 years less at EDSS
level 6 and above. The results were stable for reasonable variation of most model
parameters.CONCLUSIONS: Efficacy data from the ALLEGRO trial and Swedish cost
and quality of life data indicated potential cost savings and improved quality of life.
The most important driver of these results is the effect on disability progression.
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OBJECTIVES: To undertake a systematic benefit-risk analysis of glatiramer acetate
(GA) in relapse-remitting multiple sclerosis and clinical isolated syndrome using
controlled studies, according to the EMA guideline. METHODS: We searched
PubMed, Embase, the Cochrane Trials Register for eligible articles according to
explicit criteria to obtain trials and controlled cohort studies. Fixed and random
effects meta-analysis techniques were applied for pooling data. Qualitative and
quantitative benefit-risk analyses were performed. RESULTS: A total of 4451 pa-
tients in 15 studies were included in the meta-analysis. The overall reduction in
clinical progression was 40% (RR0.60, 95%CI: 0.48-0.75) for GA compared with
placebo/untreated and 23% (RR0.77, 95%CI: 0.65-0.92) for GA compared with in-
terferons. The rate of patients free from relapse was higher with GA compared with
placebo/standard treatment (RR1.35, 95%CI: 1.21-1.50) and similar compared with
interferons (RR1.04, 95%CI: 0.98-1.11). For GA compared with interferons there
was a13% reduction in discontinuation due to all causes (RR0.87, 95%CI: 0.72-1.04)
and a similar proportion of serious adverse events leading to discontinuation
(RR0.89, 95%CI: 0.56-1.41). Based on these results, for being free from disease
progression at 24 months against placebo/untreated, the number needed to benefit
was of 22.7 and the risk-benefit ratio was 1.69. Compared with placebo/untreated,
the relative net benefit-risk was 9% using a multi-criteria decision analysis.
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